Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant tissue plasminogen activator

Stroke

Volumn 30, Issue 10, 1999, Pages 2101-2104

  Fassbender, Klaus ^a   Dempfle, Carl Erik ^a   Mielke, Orell ^a   Schwartz, Andreas ^b   Daffertshofer, Michael ^a   Eschenfelder, Christoph ^a   Dollman, Martina ^a   Hennerici, Michael ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b University of Heidelberg ^*

Author keywords

Coagulation; Stroke, ischemic; Thrombolysis; Tissue plasminogen activator, recombinant

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; BIOCHEMICAL MARKER; D DIMER; FIBRIN MONOMER; FIBRINOPEPTIDE; HEPARIN; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FIBRIN FORMATION; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HEMOSTASIS; HEPARINIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032827021     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.10.2101     Document Type: Article

References (17)

1. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, for the ECASS Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study. JAMA. 1995;274:1017-1025.
2. The National Institute of Neurological Diseases and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
3. Riggs JE. Tissue-type plasminogen activator should not be used in acute ischemic stroke. Arch Neurol. 1996;53:1306-1308.
4. Mahaffey KW, Granger CB, O'Connor CM, Ohman EM, Bleich SD, Col JJ, Califf RM. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol. 1996;77:551-556.
5. Bounameaux H, Cirafici P, de Moerloose P, Schneider PA, Slosman D, Reber G, Unger PF. Measurement of D-dimer in plasma as diagnostic aid in suspected pulmonary embolism. Lancet. 1991;337:196-200.
6. Dempfle CE, Dollman M, Lill H, Puzzovio D, Dessauer A, Heene DL. Binding of a new monoclonal antibody against N-terminal heptapeptide of fibrin alpha-chain to fibrin polymerization site A: effects of fibrinogen and fibrinogen derivatives, and pretreatment of samples with NaSCN. Blood Coag Fibrinol 1993;4:79-86.
7. Feinberg WM, Erickson LP, Bruck D, Kittelson J. Hemostatic markers in acute ischemic stroke: association with stroke type, severity, and outcome. Stroke. 1996;27:1296-1300.
8. Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V, Waclawiw M, Cannon RO III. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med. 1997;336: 683-690.
9. Terres W, Kummel P, Sudrow A, Reuter H, Meinertz T, Hamm CW. Enhanced coagulation activation in troponin T-positive angina pectoris. Am Heart J. 1998;135:281-286.
10. Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible by antithrombin-independent inhibitors. Circulation. 1998;97:544-552.
11. Pfitzner SA, Dempfle CE, Matsuda M, Heene DL. Fibrin detected in plasma of patients with disseminated intravascular coagulation by fibrin-specific antibodies consists primarily of high molecular weight factor XIIIa-crosslinked and plasmin-modified complexes partially containing fibrinopeptide A. Thromb Haemost. 1997;78:1069-1078.
12. Aronson DL, Chang P, Kessler CM. Platelet-dependent thrombin generation after in vitro fibrinolytic treatment. Circulation. 1992;85: 1706-1712.
13. Rapold HJ, de Bono D, Arnold AE, Arnout J, De Cock F, Collen D, Verstaete M, for the European Cooperative Study Group. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase: correlation with concomitant heparin, coronary artery patency, and recurrent ischemia.. Circulation. 1992;85:928-934.
14. Scharfstein JS, Abendschein DR, Eisenberg PR, George D, Cannon CP, Becker RC, Sobel B, Cupples LA, Braunwald E, Loscalzo J. Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction: TIMI-5 Investigators: Thrombolysis in Myocardial Infarction. Am J Cardiol. 1996;78:503-510.
15. Stangl K, Laule M, Tenckhoff B, Stangl V, Gliech V, Dubel P, Grohmann A, Melzer C, Langel J, Wernecke KD, Baumann G, Ziemer S. Fibrinogen breakdown, long-lasting systemic fibrinolysis, and procoagulant activation during alteplase double-bolus regimen in acute myocardial infarction. Am J Cardiol. 1998;81:841-847.
16. Fassbender K, Mössner R, Motsch L, Kischka U, Grau A, Hennerici M. Circulating selectin-and immunoglobulin-type adhesion molecules in acute ischemic stroke. Stroke. 1995;26:1361-1364.
17. Galvani M, Abendschein DR, Ferrini D, Ottani F, Rusticali F, Eisenberg PR. Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase. J Am Coll Cardiol. 1994;24:1445-1452.